![]() ![]() The number of infections avoided by vaccination was estimated to be 643 (95%CI 236-1,237). After the third dose, VE increased to 57% (95%CI 35-71 61 infected) in the first month but rapidly declined over time, particularly after three months (24% in the fourth month and 1% afterwards). VE was 70% (95%CI 54-80 46 infected) in the first four months after the second dose and later declined to 16% (95%CI 0-43 97 infected). In the negative cohort, 1,401 SARS-CoV-2 infections were identified. In both cohorts, serum anti-S1 antibodies were high one months after the second dose, halved after six months, and returned to high levels after the third dose. VE was calculated as (1 - HR)×100.ĥ,596 HCWs were included, 4,771 in the negative and 825 in the positive cohort. Using unvaccinated person-time as reference, hazard ratios (HR) of infections and 95% confidence intervals (95%CI) were calculated with a Cox regression model adjusted for gender, age, and occupation. Vaccination was treated as a time-dependent variable. Data on infections were extracted from multiple sources (laboratory, accident reports, questionnaires). vaccine effectiveness (VE) against SARS-CoV-2 infections (either symptomatic or not) in the negative cohort. serum anti-spike-1 (anti-S1) antibody levels after vaccination 2. Data collection and follow-up covered the period -.ġ. In a hospital in Milan (Lombardy Region, Northern Italy) HCWs without ("negative cohort") and with ("positive cohort") history of SARS-CoV-2 infection or elevated serum antibody before the vaccination campaign () were included. To evaluate immunogenicity and effectiveness of BNT162b2 COVID-19 vaccine in a cohort of healthcare workers (HCWs). 14 Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan (Italy).13 School of Statistics, University of Milan-Bicocca, Milan (Italy).12 Department of Clinical Sciences and Community Health, University of Milan, Milan (Italy).11 Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy).10 Epidemiology Unit, Agency for Health Protection Brianza, Monza (Italy).9 Quality Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy). ![]() 8 Department of Biomedical Sciences for Health, University of Milan, Milan (Italy).7 Medical Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy).6 Occupational Health Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy).5 Clinical Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy).4 Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy).3 Department of Pathophysiology and Transplantation, University of Milan, Milan (Italy).1 Epidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy) 2 These authors equally contributed to this paper. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |